Ticker
ABEO

Price
2.68
Stock movement down
-0.08 (-2.90%)
Company name
Abeona Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
46.03M
Ent værdi
63.65M
Pris/omsætning
10.59
Pris/bog
2.99
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
972.00%
3 års afkast
0.50%
5 års afkast
-29.23%
10 års afkast
-17.79%
Senest opdateret: 2023-02-06

UDBYTTE

ABEO betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning10.59
Pris til egenkapital2.99
EV i forhold til salg14.64

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier17.18M
EPS (TTM)-13.28
FCF pr. aktie (TTM)-7.64

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)4.35M
Bruttofortjeneste (TTM)4.00M
Driftsindkomst (TTM)-84.63M
Nettoindkomst (TTM)-85.25M
EPS (TTM)-13.28
EPS (1 år frem)-1.79

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)91.95%
Driftsmargin (TTM)-1947.33%
Fortjenstmargin (TTM)-1961.64%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter5.73M
Nettotilgodehavender1.05M
Omsætningsaktiver i alt25.50M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver38.76M
Kreditor1.75M
Kortfristet/nuværende langsigtet gæld8.29M
Summen af kortfristede forpligtelser12.60M
Sum gæld23.35M
Aktionærernes egenkapital15.41M
Materielle nettoaktiver15.41M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-46.16M
Investeringsudgifter (TTM)2.91M
Fri pengestrøm (TTM)-49.07M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-553.12%
Afkast af aktiver-219.95%
Afkast af investeret kapital-495.00%
Kontant afkast af investeret kapital-284.93%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning2.77
Daglig høj2.84
Daglig lav2.68
Daglig volumen109K
Højeste gennem alle tider47188.00
1 års analytiker estimat21.33
Beta1.25
EPS (TTM)-13.28
Udbytte pr. aktie-
Ex-div dato22 Jul 2022
Næste dato for resultatpræsentation29 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ABEOS&P500
Nuværende prisfald fra top notering-99.99%-14.21%
Højeste prisfald-100.00%-56.47%
Højeste efterår dato17 Jun 20229 Mar 2009
Gennemsnitlig fald fra toppen-92.03%-11.49%
Gennemsnitlig tid til nyt højdepunkt404 days13 days
Maks. tid til nyt højdepunkt7569 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ABEO (Abeona Therapeutics Inc) company logo
Markedsværdi
46.03M
Markedsværdi kategori
Small-cap
Beskrivelse
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Personale
90
Investor relationer
-
SEC-indsendelser
Adm. direktør
Joao Siffert
Land
USA
By
New York
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway...
14. november 2022
Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101. Last week, the c...
8. november 2022
Abeona Therapeutics Inc (NASDAQ: ABEO) announced topline data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The VIITAL study met its two co-pri...
3. november 2022
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of i...
3. november 2022
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months met; greate...
3. november 2022
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its inv...
19. oktober 2022
Topline VIITAL™ study results expected within the next monthNEW YORK and CLEVELAND, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has ...
4. oktober 2022
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside...
22. september 2022
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel di...
13. september 2022
In this article, we discuss 10 best penny stocks to buy in September. If you want to see more stocks in this selection, check out 5 Best Penny Stocks to Buy in September. As the stock market runs red,...
8. september 2022
Næste side